Mnova Screen – Overview
Mnova Screen is an automatic analysis tool for fragment-based drug screening by NMR. An automation software for fast and efficient hit detection in fragment-based drug discovery campaigns using ligand detected NMR data.
Highlights
- Pattern recognition algorithms map your experimental data.
- Considers the use of STD, wLOGSY, T1ρ, CMPG experiments.
- Uses deconvolution to effectively pick peak, even weak signals(data points).
- Results viewer to quickly inspect your hits.
- Exports metrics of your analysis into your favorite statistical package.
Furthermore, you can also request a webinar presented last June by Dr. Mitcheell Maestre-Martinez (Mestrelab Research) and Dr. Fabrice Moriaud (Bruker) demonstrating an all-around solution for Fragment-Based Screening (FBS) by linking Bruker’s automated data acquisition methods and Mestrelab’s automated data analysis software tools.
Go back to Mnova Screen Product page,
Related posts
Optimizing Fragment-Based Drug Discovery by NMR: A Deep Dive into Mnova Screening Software Solutions
Fragment-Based Drug Discovery (FBDD) and validation of small molecules binders using NMR has emerged as a powerful method in early-stage drug development. This post explores the general use of analytical techniques and innovative screening software solutions that optimize the process, enabling researchers to identify promising drug candidates with precision.
Dr. Andrew “Dru” Namanja, Principal Research Scientist at AbbVie, will explore the potency ranking methods involving both qualitative single-point ligand concentration (Q Score) and quantitative binding affinity (KD), and how the combined utility can be used successfully to drive a Fragment-Based Drug Discovery (FBDD) campaign
Several groups in Novartis use NMR binding assays to find and validate hits during the early stages of drug discovery. They use ligand-observed NMR experiments such as STD, T1ρ, and CPMG to identify library compounds that interact with a target protein.